Amniocentesis Needle Market

Amniocentesis Needle Market By Type (100-150 mm, Larger than 150 mm, Smaller than 100 mm), By Procedure (Amniocentesis, Amnioreduction, Fetal Blood Transfusions, Amnioinfusion, Cordocentesis), By End User (Hospitals, Diagnostic Centers, Clinics) - Global Market Insights 2027

Analysis of Amniocentesis Needle market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Amniocentesis Needle Market Outlook (2022-2027)

The global amniocentesis needle market is currently valued at US$ 161 million and is estimated to stretch to a revenue of US$ 184.8 million by the end of 2027. Sales of amniocentesis needles are slated to increase at a sluggish 2.8% CAGR from 2022 to 2027.

The United States amniocentesis needle market currently accounts for an impressive value of US$ 47 million owing to the presence of developed healthcare infrastructure and the high prevalence of genetic disorders in newborns.

Report Attributes

Details

Amniocentesis Needle Market Size (2022)

US$ 161 Million

Projected Market Value (2027F)

US$ 184.8 Million

Global Market Growth Rate (2022-2027)

2.8% CAGR

United States Market Value (2022)

US$ 47 Million

Germany Market Growth Rate (2022-2027)

2.4% CAGR

Share in Syringes Market (2022)

0.7%

Key Companies Profiled

  • Smiths Medical
  • Becton, Dickinson and Company
  • Biopsybell Srl
  • Integra LifeSciences Holdings Corporation
  • Laboratoire Ccd
  • Rocket Medical PLC
  • Medline Industries Inc.
  • Medtronic PLC
  • RI.MOS. Srl
  • Cook Medical LLC
  • CooperSurgical Inc.
  • Tsunami Medical

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Amniocentesis Needle Sales Survey (2017-2021) Vs. Future Market Estimations (2022-2027)

A notable increase in the rate of pregnancies has been observed across the world and this has led to a substantial rise in demand for prenatal tests and prenatal products. Rising availability and adoption of various prenatal tests is anticipated to benefit amniocentesis needle market growth in the future.

The amniocentesis needle market accounts for around 0.7% share of the global syringes market in 2022.

Increasing recommendation of amniocentesis procedures by healthcare professionals, increasing success rate of amniocentesis, growing awareness of congenital disorders, rising awareness of Down’s syndrome, growing pregnant population, and rising investments in healthcare research and development are prime factors that could potential uplift amniocentesis needle sales through 2027.

The aforementioned factors are also anticipated to favor demand for genetic testing needles and ultrasound needles to drive the overall syringes market. The amniocentesis needle market is anticipated to evolve at a lagging CAGR of 2.8% through 2027.

This slow growth of the amniocentesis needle market can be ascribed to inhibiting factors such as high costs of prenatal surgeries, increasing incidence of fetal injuries, lack of skilled professionals, and concerns regarding the inaccuracy of certain prenatal tests.

Amniocentesis needle market forecast by Fact.MR

Increasing Incidence of Gestational Diabetes Pushing Amniocentesis Needle Sales

The world has witnessed a prominent increase in the incidence of diabetes among the general population and this had led to many health complications in several individuals. The high incidence of gestational diabetes has resulted in high demand for amniocentesis owing to the high buildup of amniotic fluid in pregnant women with diabetes.

This leads to complications in pregnancy and endangers the health of the mother and their children, which in turn drives sales of amniocentesis needles as they are used to drain the excess amniotic fluid and treat pregnant women.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Popularity of Non-invasive Prenatal Tests (NIPTs) Could Hurt Amniocentesis Needle Market

Minimally invasive procedures have gained massive popularity in recent times and this trend is expected to be more prominent over the coming years. Advancements in research and the growing availability of non-invasive procedures are expected to drive demand for non-invasive prenatal tests in the near future.

However, this could prove to be a major restraint for amniocentesis needle market growth as needles are not necessarily required for these procedures. Moreover, NIPTs reduce the risk of infection and cross-contamination, which could be a concern regarding the use of amniocentesis needles.

Companies are launching new non-invasive prenatal tests owing to high demand and advancements in minimally invasive technologies and this could hurt the growth of the amniocentesis needle market in the near future.

In April 2021, ARCEDI Biotech ApS, a Danish biotechnology organization announced the launch of a new prenatal genetic blood test to isolate and identify fetal cells in maternal blood. EVITA TEST COMPLETE™ can identify and provide a complete overview of 22 chromosome pairs and sex chromosomes to identify the sex of the fetus as early as the 12th week of pregnancy.

Concerns Regarding Accuracy of Prenatal Tests Driving Amniocentesis Needle Shipments?

The test results of prenatal tests have been a matter of controversy for a long time now and the accuracy of these tests is still debatable. As per an analysis by The Times, the positive results obtained on five common microdeletion tests performed on pregnant women were found to be inaccurate 85% of the time. The Times interviewed many researchers and combined data from several studies to create this insightful analysis.

The ambiguity around how frequent a test has to be to provide accurate results and the vague timeframe of pregnancy (i.e. first trimester, second trimester, etc.) that these tests are performed in are other factors that add to skepticism of the credibility of these tests.

All of these factors could potentially slow down the adoption of certain prenatal tests that involve the use of amniocentesis needles and this could constrain amniocentesis needle market potential across the forecast period.

North America Projected to Lead Global Amniocentesis Needle Market

Demand for amniocentesis needles is anticipated to be highest in North America and this can be attributed to the presence of developed healthcare infrastructure and the increasing pregnant population in this region.

Growth in the median age of first-time mothers and the high prevalence of genetic disorders in this region are other factors that are predicted to drive sales of amniocentesis needles through 2027. The North America amniocentesis needle market is anticipated to account for around 45% of the global market share by the end of the forecast period.

Europe is also anticipated to account for a notable market share in the global amniocentesis needle market landscape owing to the development of healthcare infrastructure and the rising availability of different prenatal procedures and tests. The Germany amniocentesis needle market is predicted to progress at a CAGR of 2.4% throughout the forecast period.

Country-wise Insights

Presence of Developed Healthcare Infrastructure & Rising Frequency of Amniocentesis in the U.S.

The market for amniocentesis needles in the United States is a highly lucrative one and is estimated to maintain this stance throughout the forecast period. High frequency of amniocentesis procedures performed, growing awareness and availability of prenatal tests, developed healthcare infrastructure, high healthcare spending potential, growth in the median age of first-time mothers, and supportive government initiatives are prime prospects that are projected to govern amniocentesis needle shipments in the country over the next five years.

Moreover, the presence of the top companies in the amniocentesis needle industry in this country is expected to further bolster the amniocentesis needle market potential. At present, the U.S. amniocentesis needle market is valued at US$ 47 million.

Category-wise Insights

Increasing Use of Amniocentesis to Determine Birth Defects & Infections

The global amniocentesis needle market, based on procedure, is segmented into amniocentesis, amnioreduction, fetal blood transfusions, amnioinfusion, and cordocentesis.

Advancements in the healthcare industry have resulted in heightened care for pregnant women and prenatal health. Amniocentesis is one of the most commonly recommended invasive prenatal tests by healthcare professionals across the world and this is expected to prominently increase the demand for amniocentesis needles for this procedure over the next five years. This procedure helps in identifying infections, birth disorders, chromosomal disorders, and other abnormalities that could affect the health of fetuses and pregnant women.

All of the aforementioned factors contribute to the dominant market share held by the amniocentesis segment. However, cordocentesis procedures are expected to witness a higher CAGR across the forecast period.

100-150 mm Needles Projected to Account for Dominant Market Share

The global amniocentesis needle market, based on type, is segmented into 100–150 mm, larger than 150 mm, and smaller than 100 mm.

The demand for 100-150 mm needles is anticipated to account for a dominant market share across the forecast period. These types of needles are used for females with a normal body mass index (BMI), and the number of pregnant women with this BMI is high, which is expected to bolster sales of 100-150 mm needles over the next five years.

However, the increasing number of overweight women across the world is anticipated to drive demand for needles larger than 150 mm at a CAGR of around 1.5% as they are used for women with higher BMI.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Competitive Landscape

The global amniocentesis needle market is packed with competition on a local level and this is expected to impact the sales of key companies in the amniocentesis needle marketplace. Major and minor market players are expected to focus on product innovation to advance their sales potential and opt for organic as well as inorganic growth strategies.

This revised amniocentesis needle industry survey by analysts at Fact.MR, a market research and competitive intelligence provider, gives a detailed assessment of opportunities in the amniocentesis needle market for new and established players and has profiled market players such as Laboratoire Ccd, Rocket Medical PLC, and Medline Industries Inc.

Segments of Amniocentesis Needle Industry Research

  • By Type :

    • 100–150 mm
    • Larger than 150 mm
    • Smaller than 100 mm
  • By Procedure :

    • Amniocentesis
    • Amnioreduction
    • Fetal Blood Transfusions
    • Amnioinfusion
    • Cordocentesis
  • By End User :

    • Hospitals
    • Diagnostic Centers
    • Clinics
    • Others
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

- FAQs -

At what rate will the market progress in Germany?

The Germany amniocentesis needle market is anticipated to exhibit expansion at a CAGR of around 2.4%.

What is the estimated size of the market for amniocentesis needles for 2027?

The global amniocentesis needle market is estimated to reach US$ 184.8 million by 2027.

At what rate is the market projected to grow?

From 2022 to 2027, demand for global amniocentesis needles is set to evolve at 2.8% CAGR.

Which regional market accounts for a dominant market share?

North America is projected to account for a major market share of around 45% by 2027-end.

What is the current revenue of the amniocentesis needle market?

Worldwide sales of amniocentesis needles account for a value of US$ 161 million.

Who are the key players in this market?

Smiths Medical, Becton, Dickinson and Company, Biopsybell Srl, Integra LifeSciences Holdings Corporation, Laboratoire Ccd, Rocket Medical PLC, Medline Industries Inc., and Medtronic PLC are key amniocentesis needle manufacturers.

Amniocentesis Needle Market

Schedule a Call